Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Discontinued
Reference number: GID-TA11228
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early October 2023 when we will write to you about how you can get involved.